Trellis Vitality review

The product page supplies the meaningful price comparison

Trellis Vitality lists semaglutide at $150 for a one-month plan and tirzepatide at $199. Three-month equivalents are $140 and $189, while six-month equivalents are $133 and $179. The lower amounts belong to longer commitments, rather than a new month-to-month rate available without choosing that term. A patient should ask for the complete payment and renewal schedule before dividing a plan into a household budget. The clearest flexible comparison uses the one-month amounts for the actual intended medication.

The homepage emphasizes a $0 assessment rather than publishing the medication grid, so its free entry point should not become the program's treatment price. The product page says all doses share the same rate, with no consultation or recurring platform fee on top. Those are useful claims to connect to the selected prescription and supply. Ask which services and tests are included and how a dose or product change affects a paid term. An assessment can be free while the clinical decision still leads to an unsuitable or unaffordable treatment offer.

A named pharmacy makes the preparation easier to identify

Trellis names Vials Rx as its compounding pharmacy and describes it as state licensed and cGMP compliant. That provides a concrete dispenser to ask about, while the company's description of compliance is not proof that a compounded preparation is FDA-approved. Trellis expressly acknowledges that the finished medication is not approved. Ask for the actual formulation, concentration and instructions, particularly when transferring from another supply. A familiar active ingredient does not make two compounded products identical or allow the patient to carry over another vial's directions independently.

The program describes review by US board-certified clinicians without naming an individual professional in advance. Ask who will assess the patient, which practice holds the relationship and how follow-up reaches the responsible prescriber. A network can provide care without guaranteeing the same clinician at every contact. The practical question is what support remains available between orders and whether a live discussion can be arranged when needed. A low product price and free opening assessment are most useful when paired with an understandable continuing care arrangement.

The longer term needs its own cancellation explanation

The three- and six-month discounts should be evaluated against the full obligation and unused-supply rules. Ask what happens if prescribing changes, the patient needs to pause or a location change affects eligibility. Stopping future renewal is different from obtaining a refund for money already paid or medication already prepared. The available price grid explains the term choices but does not settle every financial outcome. Obtain the actual agreement rather than infer flexibility from a per-month label attached to a longer protocol.

Trellis advertises fifty-state access, which still needs confirmation for the individual prescription, consultation location and delivery address. Its offering here is compounded injectable care without an established oral or approved-brand alternative. Public information also does not provide a developed postpartum, breastfeeding or PCOS pathway, so relevant needs require direct discussion and coordination. Trellis is particularly useful to consider when an identifiable pharmacy and a readable flat-dose ladder meet the patient's priorities. The decision should rest on actual support, local access and the selected term, rather than an unsupported claim to be the cheapest service with a named dispenser.